The NINDS recombinant tissue plasminogen activator trials compared IV recombinant tissue plasminogen activator, 0.9 mg/kg (maximum, 90 mg), with placebo administered within 3 hours of symptom onset.7 The NINDS study comprised 2 trials (n = 291 in part 1 and n = 333 in part 2); part 1 measured outcomes at 24 hours, and part 2 measured outcomes at 90 days. Because part 1 also measured outcome at 90 days, the overall results were combined by the investigators and are summarized in Table 2. The primary outcomes assessed for these trials were the BI and the mRS, the same as those for the ECASS I. In addition, 2 other outcomes were measured. The first was the National Institute of Health Stroke Scale (NIHSS) score, which is an 11-item (42-point) neurologic examination that tests cognition, level of consciousness, eye movements, visual fields, motor ability, sensation, and ataxia. It is most often used to grade the stroke severity at onset. Scores of 14 or higher are considered a moderate to large stroke.8 The initial NIHSS score is often compared with a follow-up score at 90 days to categorize improvement. An NIHSS score of 0 or 1 at follow-up is considered an excellent result. Another outcome measure was the Glasgow Outcome Scale, a 5-point global outcome scale with 1 representing death and 5 representing good recovery.